Use of Autologous, Adult Adipose-Derived Stem/Stromal Cells in Inflammatory Bowel Disease (ADcSVF-IBD)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02952131|
Recruitment Status : Recruiting
First Posted : November 2, 2016
Last Update Posted : November 8, 2018
Inflammatory Bowel Disease (IBD) is a group of inflammatory conditions of the small bowel and colon. Main types include Ulcerative Colitis and Crohn's Disease. Symptoms are often difficult to distinguish except for location and nature of changes. IBD complex arises with interaction of environmental, genetic factors, immunological responses, and chronic and recurring inflammation.
Many factor appear as contributory, but no single set of issues appear to explain the process. Microbiota, intestinal wall granulation or breach, dietary, genetic predisposition all appear to factors. Treatment is often reactive or suppressive medications, neither of which appears to reverse the disease processes. This study explores the value of a complex group of adipose-derived stem/stromal cells (AD-cSVF) in the disease process.
|Condition or disease||Intervention/treatment||Phase|
|Inflammatory Bowel Diseases||Procedure: Lipoaspiration Procedure: AD-cSVF Procedure: Normal Saline IV||Phase 1 Phase 2|
IBD often presents clinically as abdominal pain, diarrhea (with and without blood), fever, weight loss, failure to thrive, and many related symptoms. Complications of the disorders may also include anemia, skin rashes, arthritis, severe chronic fatigue, and eye inflammatory changes.
It is felt that IBD disorders may be caused by combination of environmental, immune, genetic, and bacterial factors. Results of these issues produce a chronic inflammatory disorder, in which the immune system attacks the gastrointestinal tract, perhaps directed by certain microbial antigens. The group appears not to be a pure autoimmune disease reaction, but may relate to a immunodeficiency state.
There are no medications or surgical procedures that are known to cure the diseases. Most are aimed at reduction of symptoms, maintain remissions, and try to prevent relapses. Temporary anti-inflammatory medications may improve the acute process, followed by methotrexate or thiopurine to maintain remission states. Surgery appears important in cases of perforation, abscesses, obstructions, or cancer management.
Actual occurrence is unknown, as there are more than Crohn's Disease and Ulcerative Colitis which appear related. It is estimated that more than 35,000 deaths were reported in 2010. Crohn's Disease alone appears to affect 3.2 per 1000 people in Europe and North America alone.
The usual onset of symptoms may appear before actual diagnoses are made, with typical diagnoses occurring between 15-30 years of age. Lead by abdominal pain symptoms (usually lower right quadrant) and the recurrent periods of flare and remission. Many dietary, bacterial, antimicrobials, and environmental factors receive attention, some new interest in evaluating alternative therapeutic modalities to deal of issues of immune system. Use of the immune privileged cellular agents held within the AD-cSVF is proposed to help with the inflammatory contributors as well as the modulation of inflammation which favors chronic wound healing and avascular systems. Known to provide secretory antibiotic (ll-37) contributions, some thought of pro- and anti-microbials, may prove of value in those areas specifically. Cytokine and growth factors implications at the lesion sites remain to be poorly understood, but those experienced in biocellular regenerative therapies have experienced contributions to healing and prevention of recurrences of ulcerative skin lesions.
Harvest of autologous of adipose-derived tissue stromal vascular fraction (AD-tSVF) is a proven rich resource of microvascular stem/stromal cell elements with well documented growth factor and cytokine contributors. With the advent of safe, measurable, and efficacious and reproducible numbers in a closed isolation environment, the ability to isolate and concentrate a cell-only product. This AD-cSVF is capable of reintroduction into patients, via a Normal Saline Solution, via parenteral route.
This study is intended to evaluate the safety (adverse outcomes) and efficacy of using autologous cellular therapy in cases of IBD.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||100 participants|
|Intervention Model:||Parallel Assignment|
|Official Title:||Use of Autologous Adult Adipose-Derived Stem/Stromal Cells in Inflammatory Bowel Disease|
|Study Start Date :||November 2016|
|Estimated Primary Completion Date :||November 2019|
|Estimated Study Completion Date :||November 2020|
Experimental: Lipoaspiration Arm 1
Acquisition of Adipose-Derived tissue Stromal Vascular Fraction (AD-tSVF) via closed syringe harvest subdermal fat
Closed Syringe Harvesting Autologous Subdermal Fat
Experimental: AD-cSVF Arm 2
Isolation of cellular stem/stromal cells from subdermal adipose-derived cellular stromal vascular fraction (AD-cSVF)
Use of Centricyte 1000 to isolate adipose stem/stromal cells via centrifugation
Experimental: Normal Saline IV Arm 3
Normal Saline IV with AD-cSVF cells
Procedure: Normal Saline IV
Normal Saline IV containing AD-cSVF
- Safety: Inflammatory Bowel Disease [ Time Frame: 12 months Evaluate Function and Adverse Events ]Inflammatory Bowel Disease to be addressed as occurrence or frequency of adverse event during study. Includes vital signs, complete blood count, and disease progression
- Efficacy: Quality of life index , Inflammatory Bowel Disease Questionnaire(IBD-QoL) [ Time Frame: 1 month, 6 month, 1 year ]Comparison of response if it improves at least 30%
- Change from Baseline in C Reactive Protein (CRP) [ Time Frame: 0, 2 weeks, 8 weeks, 12 weeks ]Blood draw and laboratory measure of CRP as reflection of inflammatory baseline change
- Efficacy: Change in Baseline of Modified Truelove-Witts Score (MTW) [ Time Frame: 0, 4 weeks, 12 weeks ]Remission is considered if below 11, and response if it diminishes at least 30%
- Efficacy: Change in Baseline in Lichtiger Index [ Time Frame: 0, 12 weeks, 6 months ]Remission considered if reaching 0 point, and response if the score diminishes from pretreatment level
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02952131
|Contact: Robert W Alexander, MD, MDfirstname.lastname@example.org|
|Contact: Nancy Smith, MA, ORTemail@example.com|
|United States, Montana|
|Stevensville, Montana, United States, 59870|
|Contact: Nancy Smith, MA, ORT 406-777-4477 firstname.lastname@example.org|
|Contact: Nancy L Smith, MA,ORT 4067774477 GARM-USA@gmail.com|
|Stevensville, Montana, United States, 59870|
|Contact: Glenn C Terry, MD 706-566-9141 email@example.com|
|Contact: Heather Terry 17065669141 firstname.lastname@example.org|
|Principal Investigator: Glenn C Terry, MD|
|Principal Investigator: Robert W Alexander, MD|
|Principal Investigator:||Robert W Alexander, MD||Healeon Medical Inc|
|Study Director:||Glenn C Terry, MD||Global Alliance for Regenerative Medicine (GARM)|